Who should get the HPV vaccine? Usage expands amid debate.

Journal of the National Cancer Institute

Volumn 102, Issue 12, 2010, Pages 838-840

  Peres, Judy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ARTICLE; CHILD; COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; ECONOMICS; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; CHILD; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; FEMALE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; TUMOR VIRUS INFECTIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77953714477     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq229     Document Type: Article

References (0)